Quick answer: what is tirzepatide?
- Medication type: Dual incretin agonist that activates GLP‑1 and GIP receptors.
- Main uses: Improves blood glucose in adults with type 2 diabetes; used for chronic weight management under certain brand approvals.
- Brands: Mounjaro (type 2 diabetes), Zepbound (weight management). Names vary by country.
- Dosing: Once weekly via subcutaneous injection using prefilled pens; gradual dose escalation is common. See the Tirzepatide Dosage Guide.
- In Australia: Mounjaro is TGA‑approved for type 2 diabetes and PBS‑subsidised for specific criteria. Zepbound is TGA‑approved for weight management; private access and supply can vary. See Is Tirzepatide Legal in Australia?
How tirzepatide works: GLP‑1 + GIP dual agonism
Incretins are hormones released from the gut after eating. GLP‑1 and GIP help the pancreas release insulin appropriately, reduce glucagon when glucose is high, slow stomach emptying and influence appetite centres in the brain.
Tirzepatide binds to both GLP‑1 and GIP receptors. This dual mechanism can:
- enhance glucose‑dependent insulin release and improve HbA1c
- reduce appetite and energy intake, supporting weight loss
- slow gastric emptying, which may help satiety but can cause nausea when starting or increasing dose
See our GLP‑1 Australia Guide to understand how GLP‑1 medicines work more broadly.
What tirzepatide is used for
Type 2 diabetes (T2D)
Clinical trials (SURPASS program) show tirzepatide can substantially reduce HbA1c (often by ~1.5–2.5 percentage points depending on dose and baseline) and support weight loss in adults with T2D, alone or added to medicines like metformin. Many participants achieved HbA1c targets while losing weight.
Weight management
In people without diabetes but living with obesity or overweight with comorbidities, tirzepatide (SURMOUNT program) produced average weight reductions that increased with dose and time. At higher doses over ~72 weeks, mean weight loss exceeded 15% and approached or surpassed 20% in some cohorts. Individual results vary and require diet, activity and medical supervision.
For a deeper dive, see Tirzepatide Benefits and Tirzepatide for Weight Loss.
Tirzepatide vs semaglutide and next‑gen options
- Compared with semaglutide (a GLP‑1 only agonist), tirzepatide’s dual action has shown greater average weight loss at higher doses in trials. See Semaglutide vs Tirzepatide.
- Retatrutide (a triple agonist in research) is being studied as a possible next step. See Retatrutide vs Tirzepatide and Retatrutide vs Semaglutide.
- For a broader market view, read Weight Loss Injections Australia.
Dosing basics (overview only)
Tirzepatide is injected once weekly. Many protocols start at 2.5 mg once weekly and step up gradually (for example 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) based on response and tolerability. Do not change your dose without medical advice.
- Route: Subcutaneous (abdomen, thigh, or upper arm)
- Form: Prefilled multi‑dose pens with titration steps
- Missed dose rules and injection technique matter for outcomes and side effects
See the detailed Tirzepatide Dosage Guide and Peptide Injection Guide.
Side effects, warnings and safety
The most common effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and reduced appetite—often milder after the body adjusts or with slower titration. Less common but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and rare hypersensitivity reactions.
- Contraindications and cautions may include a history of pancreatitis, certain endocrine tumours, severe GI disease, and pregnancy/breastfeeding. Review your history with a doctor.
- Drug interactions and combined effects (for example, with sulfonylureas or insulin) may increase hypoglycaemia risk—medical supervision is required.
Read the full Tirzepatide Side Effects guide and discuss your circumstances with a qualified professional.
Australian access, brands and costs
- Brands: Mounjaro (type 2 diabetes), Zepbound (weight management). Availability and stock fluctuate.
- Prescription: Tirzepatide is prescription‑only in Australia. See Tirzepatide Prescription Australia and Is Tirzepatide Legal in Australia?
- PBS: Mounjaro is PBS‑listed for eligible adults with type 2 diabetes meeting set criteria. Weight‑management indications are typically private (non‑PBS) unless policies change.
- Costs: Private prices vary. See Tirzepatide Cost Australia. For brand‑specific context also see Mounjaro Australia Guide.
Results timeline: when changes are usually noticed
Some people notice appetite changes in the first 1–2 weeks, with steadier weight change emerging over months as doses are titrated and lifestyle changes are maintained. Glycaemic improvements can appear within weeks in T2D. Long‑term results depend on adherence, dose, and supportive habits.
Explore expected milestones in the Tirzepatide Results Timeline and learn how this compares to Semaglutide Results Timeline.
Frequently asked questions
Is tirzepatide a GLP‑1?
It targets GLP‑1 and GIP receptors—so it is broader than a GLP‑1‑only medicine. See GLP‑1 Australia Guide.
What is the difference between Mounjaro and Zepbound?
Both contain tirzepatide. Mounjaro is indicated for type 2 diabetes; Zepbound is indicated for chronic weight management (criteria apply). Availability differs by country and over time in Australia.
How does tirzepatide compare to semaglutide for weight loss?
Head‑to‑head studies suggest greater average weight loss with tirzepatide at higher doses. See Semaglutide vs Tirzepatide.
Will weight return if I stop?
Weight regain is common when treatment stops if lifestyle factors and medical support are not maintained. Ongoing care plans matter.
Can tirzepatide be used with metformin or insulin?
Often yes for T2D, but risks like hypoglycaemia must be managed by your prescriber.
Who might consider tirzepatide for weight management?
Adults with obesity (BMI ≥30) or BMI ≥27 with weight‑related comorbidities under a clinician’s supervision. See Tirzepatide for Obesity and Tirzepatide for Insulin Resistance.
What should I read next?
Start with Side Effects, Dosage, and our Buy Tirzepatide Australia guidance on safe, lawful access.
Ask for help: talk to a clinician‑supported team
Have questions about eligibility, brands, dosing or side effects? Send a message and a clinician‑supported team can point you to appropriate next steps. We do not sell medications; this is informational guidance only.
Prefer a short overview first? See the Mounjaro Australia Guide or the Weight Loss Injections Australia hub.
Final takeaway
Tirzepatide is a dual GLP‑1/GIP agonist that can improve blood sugar and support substantial weight loss for eligible adults under medical supervision. Outcomes depend on dose, adherence and lifestyle, and safe use requires a prescription and monitoring.